This document discusses potential immune-based therapies for modulating atherosclerosis and vulnerable plaque. It suggests that targeting specific antigens, co-stimulatory molecules, cytokines, vaccines, recombinant proteins, antibodies, cells, or small molecule drugs could help shift the immune response away from pathogenic Th1 immunity toward protective Th2 immunity. Certain cytokines like IL-10 and TGFβ may be protective, while IFNγ and TNFα aggravate disease. Immunization experiments with oxidized LDL and heat shock protein 65 have shown promise in reducing lesions in animal models. Statins and pentoxifyllin may also help by inhibiting Th1 responses. However, general immunosuppression poses side effects, so focused immune modulation is a more viable strategy